Patents by Inventor Hirotsugu Komatsu

Hirotsugu Komatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150045352
    Abstract: The present invention provides a composition controlling a pH range of release and/or a release rate, which contains (i) a thienotriazolodiazepine compound of the formula (I) and (ii) at least one kind of ingredient selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer and/or a surfactant, as well as a production method thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Kazuyoshi SAGARA, Tomoyuki OMURA, Hirofumi SAMEMOTO, Hirotsugu KOMATSU
  • Patent number: 8883777
    Abstract: The present invention provides a composition controlling a pH range of release and/or a release rate, which contains (i) a thienotriazolodiazepine compound of the formula (I) and (ii) at least one kind of ingredient selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer and/or a surfactant, as well as a production method thereof.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: November 11, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kazuyoshi Sagara, Tomoyuki Omura, Hirofumi Samemoto, Hirotsugu Komatsu
  • Publication number: 20120202798
    Abstract: The present invention provides a composition controlling a pH range of release and/or a release rate, which contains (i) a thienotriazolodiazepine compound of the formula (I) and (ii) at least one kind of ingredient selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer and/or a surfactant, as well as a production method thereof.
    Type: Application
    Filed: April 17, 2012
    Publication date: August 9, 2012
    Inventors: Kazuyoshi SAGARA, Tomoyuki Omura, Hirofumi Samemoto, Hirotsugu Komatsu
  • Publication number: 20090012064
    Abstract: The present invention provides a composition controlling a pH range of release and/or a release rate, which contains (i) a thienotriazolodiazepine compound of the formula (I) and (ii) at least one kind of ingredient selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer and/or a surfactant, as well as a production method thereof.
    Type: Application
    Filed: August 5, 2008
    Publication date: January 8, 2009
    Inventors: Kazuyoshi Sagara, Tomoyuki Omura, Hirofumi Samemoto, Hirotsugu Komatsu
  • Publication number: 20070232614
    Abstract: The present invention provides a therapeutic drug for non-viral hepatitis, which contains a piperazine compound represented by the following formula (I) or pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: April 27, 2005
    Publication date: October 4, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Tetsuko Fukuda, Akira Mogami, Masao Hisadome, Kunitomo Adachi, Hirotsugu Komatsu
  • Publication number: 20030130268
    Abstract: The present invention provides a composition controlling a pH range of release and/or a release rate, which contains (i) a thienotriazolodiazepine compound of the formula (I) 1
    Type: Application
    Filed: December 16, 2002
    Publication date: July 10, 2003
    Inventors: Kazuyoshi Sagara, Tomoyuki Omura, Hirofumi Samemoto, Hirotsugu Komatsu
  • Patent number: 5721231
    Abstract: N-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno ?3,2-f!?1,2,4!triazolo?4,3-a!?1,4!diazepin-6-yl )-N'- (2-methoxyphenyl)urea, optical isomers thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention strongly and selectively inhibit the expression of VCAM-1 and have an inhibitory effect on leukocyte adhesion to vascular endothelial cells. Accordingly, the compounds of the present invention can be used as cell adhesion inhibitors for prophylaxis or treatment of various diseases in which cell adhesion is involved in the onset and progress thereof.
    Type: Grant
    Filed: September 28, 1995
    Date of Patent: February 24, 1998
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Minoru Moriwaki, Hiroyuki Kitani, Syuji Ehara, Hirotsugu Komatsu, Mariko Amano
  • Patent number: 5712274
    Abstract: Thienotriazolodiazepine compounds of the formula (1) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof, and pharmaceutical use thereof. The compounds of the present invention are useful as preventive and therapeutic drugs for inflammatory diseases and allergic diseases, in which cell adhesion is involved.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: January 27, 1998
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Hiroyuki Sueoka, Shuji Ehara, Haruhito Kobayashi, Takeshi Arichi, Hirotsugu Komatsu
  • Patent number: 5686479
    Abstract: An immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor, each containing a thienotriazolodiazepine compound wherein the 2-position of its diazepine ring is alkylated as an active ingredient, an immunosuppression method, an autoimmune disease treating method, an immunosuppression enhancing method and a cell adhesion inhibiting method, each of which comprising administering the compound, and uses of the compound for the production of an immunosuppressive drug, an autoimmune disease treating drug, an immunosuppression enhancing drug and a cell adhesion inhibitor.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: November 11, 1997
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Takeki Okumoto, Kenji Chiba, Yukio Hoshino, Hirotsugu Komatsu, Mariko Nagasawa, Hidekazu Aratani, Michio Terasawa, Minoru Moriwaki
  • Patent number: 5124331
    Abstract: 3,4-Dihydrothieno[2,3-d]pyrimidine compounds having immunoregulating and carcinostatic actions of the general formula ##STR1## wherein A represents a C.sub.1-4 alkylene; R.sup.1 represents hydrogen, an alkyl, an aryl which may be substituted or --N(R.sup.7)(R.sup.8); R.sup.2, R.sup.3 and R.sup.4 represent hydrogen, a halogen, hydroxy, an alkyl which may be substituted by a halogen, an alkoxy, nitro, cyano or --N(R.sup.9)(R.sup.10); R.sup.5 represents hydrogen, a halogen, nitro, amino, cyano, an alkyl or an alkoxycarbonyl; R.sup.6 represents hydrogen, a halogen, nitro, amino, cyano, an alkyl, an alkoxycarbonyl, a halogenosulfonyl or --SO.sub.2 N(R.sup.12)(R.sup.13); or R.sup.5 and R.sup.6 may, taken together, form a C.sub.3-6 alkylene chain, and their pharmaceutical use.
    Type: Grant
    Filed: November 2, 1989
    Date of Patent: June 23, 1992
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Masafumi Arita, Yoshitaka Fukumasu, Mitsuharu Sano, Yukio Hoshino, Hirotsugu Komatsu
  • Patent number: 5037958
    Abstract: A new immunosuppressive factor derived from human T cell leukemia cells characterized by the following properties:(1) molecular weight: 45,000 to 65,000 daltons and 150,000 to 200,000 daltons by gel filtration, and approximately 31,000 daltons by SDS-polyacrylamide gel electrophoresis;(2) isoelectric point: 4.6 to 4.8;(3) being elutable at a concentration of 0.31 to 0.32 M sodium chloride by FPLC-Mono Q anion exchange chromatography;(4) not adsorbable to immobilized concanavalin A Sepharose or blue Sepharose;(5) resistant to deoxyribonuclease, ribonuclease, papin and periodic acid but sensititive to trypsin, .alpha.-chymotrypsin or pronase;(6) stable at pH 2 to 10;(7) stable for a long time at 4.degree. C. but partially inactivated by heat treatment at 56.degree. C. or 90.degree. C. for 30 minutes;(8) not inhibitable by 2-mercaptoethanol, levamisole, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, .alpha.
    Type: Grant
    Filed: December 12, 1987
    Date of Patent: August 6, 1991
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Yoshiyuki Hashimoto, Kenji Chiba, Hirotsugu Komatsu, Takeki Okumoto